JP2024526191A - セレブロン結合化合物、その組成物及びそれによる治療方法 - Google Patents

セレブロン結合化合物、その組成物及びそれによる治療方法 Download PDF

Info

Publication number
JP2024526191A
JP2024526191A JP2023579304A JP2023579304A JP2024526191A JP 2024526191 A JP2024526191 A JP 2024526191A JP 2023579304 A JP2023579304 A JP 2023579304A JP 2023579304 A JP2023579304 A JP 2023579304A JP 2024526191 A JP2024526191 A JP 2024526191A
Authority
JP
Japan
Prior art keywords
mmol
trans
alkyl
cyclohexyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526191A5 (https=
Inventor
ディ アレキサンダー，マシュー
ディ コレア，マシュー
ダルビー，ディーパク
ヘザー シャロン グラント，バージニア
ハンセン，ジョシュア
サード，ロイ エル ハリス，ザ
ジェイ ホーン，エバン
ホアン，デフア
メイン，クリストファー
ノリス，スティーブン
プラントヴァン－クレニツキー，ヴェロニク
ジェイ サピエンザ，ジョン
テラニ，リダ
ダブリュー ホワイトフィールド，ブランドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2024526191A publication Critical patent/JP2024526191A/ja
Publication of JP2024526191A5 publication Critical patent/JP2024526191A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023579304A 2021-06-25 2022-06-24 セレブロン結合化合物、その組成物及びそれによる治療方法 Pending JP2024526191A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163215243P 2021-06-25 2021-06-25
US63/215,243 2021-06-25
PCT/US2022/034921 WO2022272074A1 (en) 2021-06-25 2022-06-24 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Publications (2)

Publication Number Publication Date
JP2024526191A true JP2024526191A (ja) 2024-07-17
JP2024526191A5 JP2024526191A5 (https=) 2025-06-30

Family

ID=84543920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579304A Pending JP2024526191A (ja) 2021-06-25 2022-06-24 セレブロン結合化合物、その組成物及びそれによる治療方法

Country Status (6)

Country Link
US (1) US20240368118A1 (https=)
EP (1) EP4359407A4 (https=)
JP (1) JP2024526191A (https=)
KR (1) KR20240026939A (https=)
CN (1) CN117561249A (https=)
WO (1) WO2022272074A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4692061A1 (en) * 2023-03-29 2026-02-11 Aevis Bio, Inc. Low-molecular-weight compound having cereblon-binding activity, and use thereof
AU2024298923A1 (en) 2023-07-25 2026-01-22 Monte Rosa Therapeutics Ag Substituted piperidinediones for targeted protein degradation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504836A (ja) * 2016-01-11 2019-02-21 ヤンセン ファーマシューティカ エヌ．ベー． アンドロゲン受容体アンタゴニストとしての置換チオヒダントイン誘導体
JP2020506922A (ja) * 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
US20200199073A1 (en) * 2018-12-19 2020-06-25 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
JP2020528918A (ja) * 2017-07-28 2020-10-01 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． アンドロゲン受容体の標的化分解のための化合物および方法
WO2021053495A1 (en) * 2019-09-16 2021-03-25 Novartis Ag Bifunctional degraders and their methods of use
WO2021262810A1 (en) * 2020-06-24 2021-12-30 Celgene Corporation Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． ターゲティングされたアンドロゲン受容体分解のための化合物および方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504836A (ja) * 2016-01-11 2019-02-21 ヤンセン ファーマシューティカ エヌ．ベー． アンドロゲン受容体アンタゴニストとしての置換チオヒダントイン誘導体
JP2020506922A (ja) * 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
JP2020528918A (ja) * 2017-07-28 2020-10-01 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． アンドロゲン受容体の標的化分解のための化合物および方法
US20200199073A1 (en) * 2018-12-19 2020-06-25 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
WO2021053495A1 (en) * 2019-09-16 2021-03-25 Novartis Ag Bifunctional degraders and their methods of use
WO2021262810A1 (en) * 2020-06-24 2021-12-30 Celgene Corporation Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ACS OMEGA, vol. Vol.3(9), JPN6026010209, 2018, pages 11163 - 11171, ISSN: 0005818238 *

Also Published As

Publication number Publication date
EP4359407A1 (en) 2024-05-01
US20240368118A1 (en) 2024-11-07
CN117561249A (zh) 2024-02-13
WO2022272074A1 (en) 2022-12-29
KR20240026939A (ko) 2024-02-29
EP4359407A4 (en) 2025-04-30

Similar Documents

Publication Publication Date Title
JP7778095B2 (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP7781792B2 (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP7781083B2 (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP2024526191A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP2024526182A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP2024526192A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
HK40091356B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091356A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091357B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091357A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250620

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260317